This seems to be an important point of contention (not just for PPHM). Many folks here say a drug doesn't have to show any efficacy in order to proceed to a phase III trial; just exhibit safety. Others say, no, a drug must have indications of efficacy in addition to safety in order to proceed.
Market Data 
Markets 
AI
